Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18923012 | 0.84 | DPP4 (0.32) | CYP1A2CYP2C9CYP2D6ALDH1A1TSHR | |
| SCHEMBL18923114 | 0.81 | GRIN2B (0.46) | USP2JAK3TSHRSMN1; SMN2 | |
| SCHEMBL16980481 | 0.81 | GRIN2B (0.46) | USP2JAK3TSHRSMN1; SMN2 | |
| SCHEMBL10187246 | 0.81 | IDO1 (0.32) | CYP1A2CYP2C9CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL4743137 | 0.79 | DPP4 (0.35) | MAPK1CYP3A4TSHRCYP2C19DPP4 | |
| SCHEMBL16980483 | 0.79 | DPP4 (0.35) | MAPK1CYP3A4TSHRCYP2C19DPP4 | |
| SCHEMBL16563021 | 0.79 | DPP4 (0.35) | MAPK1CYP3A4TSHRCYP2C19DPP4 | |
| SCHEMBL4742170 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2D6ALDH1A1USP2 | |
| SCHEMBL4742521 | 0.79 | POLB (0.38) | CYP1A2CYP2C9CYP2D6ALDH1A1TSHR | |
| SCHEMBL4742148 | 0.78 | ALDH1A1 (0.44) | CYP1A2CYP2C9CYP2D6ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | CYP1A2 588/4885CYP2C9 520/4885CYP2D6 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.